Authors: SVENSSON J OHLSSON C JANSSON JO MURPHY G WYSS D KRUPA D CERCHIO K POLVINO W GERTZ B BAYLINK D MOHAN S BENGTSSON BA

Citation: J. Svensson et al., TREATMENT WITH THE ORAL GROWTH-HORMONE SECRETAGOGUE MK-677 INCREASES MARKERS OF BONE-FORMATION AND BONE-RESORPTION IN OBESE YOUNG MALES, Journal of bone and mineral research, 13(7), 1998, pp. 1158-1166

Authors: DIXON R SMITH DA POLVINO W

Citation: R. Dixon et al., FLUOXETINE HAS NO EFFECTS ON THE PHARMACOKINETICS, PHARMACODYNAMICS OR SAFETY PROFILE OF ZOLMITRIPTAN (ZOMIG(TM)), Neurology, 50(4), 1998, pp. 5004-5004

Authors: SVENSSON J LONN L JANSSON JO MURPHY G WYSS D KRUPA D CERCHIO K POLVINO W GERTZ B BOSEAUS I SJOSTROM L BENGTSSON BA

Citation: J. Svensson et al., 2-MONTH TREATMENT OF OBESE SUBJECTS WITH THE ORAL GROWTH-HORMONE (GH)SECRETAGOGUE MK-677 INCREASES GH SECRETION, FAT-FREE MASS, AND ENERGY-EXPENDITURE, The Journal of clinical endocrinology and metabolism, 83(2), 1998, pp. 362-369

Authors: FRANC JE KOLLIA G KATES RE POLVINO W SALAZAR DE

Citation: Je. Franc et al., AVITRIPTAN COADMINISTRATION DELAYS ACETAMINOPHEN ABSORPTION BUT DOES NOT ALTER ITS METABOLISM, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 22-22

Authors: POLVINO W SCIBERRAS D GERTZ B CHENG H STEPANAVAGE M WITTREICH J OLAH T EDWARDS M MANT T

Citation: W. Polvino et al., MK-462 - 1ST HUMAN-EXPERIENCE WITH A NOVEL 5-HT1D AGONIST, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 129-129